Mitchell McCord, DO
Family Medicine · Evansville, INNPI 1740849553
Payments from drug & device makers
Across 341 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$529
- Pfizer$520
- Amgen$473
- AstraZeneca$355
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$311
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,387100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $1,105 |
| Novo Nordisk | 42 | $529 |
| Pfizer | 30 | $520 |
| Amgen | 34 | $473 |
| AstraZeneca(2 entities) | 13 | $355 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $311 |
| Otsuka America Pharmaceutical, Inc. | 13 | $264 |
| Novartis | 23 | $259 |
| GSK | 13 | $234 |
| Axsome Therapeutics, Inc. | 15 | $210 |
| Lilly USA, LLC | 12 | $186 |
| Merck | 8 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $90 |
| Corium, LLC | 6 | $82 |
| Bayer | 4 | $63 |
| Inari Medical, Inc. | 1 | $61 |
| Inspire Medical Systems, Inc. | 3 | $56 |
| Mylan Specialty L.p. | 2 | $51 |
| Exact Sciences | 3 | $42 |
| Pulmonx Corporation | 1 | $39 |
| Phathom Pharmaceuticals, Inc. | 4 | $38 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $30 |
| Dynavax Technologies Corporation | 2 | $25 |
| Astellas Pharma US Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Ardelyx, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,387 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $62,759 |
| OzempicSemaglutide | 54 | $60,066 |
| JardianceEmpagliflozin | 55 | $54,212 |
| VraylarCariprazine Hcl | 37 | $52,800 |
| FarxigaDapagliflozin Propanediol | 40 | $29,592 |
| Spiriva RespimatTiotropium Bromide | 25 | $19,336 |
| UbrelvyUbrogepant | 11 | $17,781 |
| Repatha SureclickEvolocumab | 14 | $16,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,837 |
| XareltoRivaroxaban | 11 | $11,811 |
| JanuviaSitagliptin Phosphate | 15 | $9,298 |
| LinzessLinaclotide | 14 | $8,448 |
| BelsomraSuvorexant | 16 | $6,794 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,503 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $4,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy, Linzess | $1,105 | $79,02962 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $18 | $73,54880 claims |
| PfizerEliquis | $520 | $62,75950 claims |
| Novo NordiskOzempic | $529 | $60,06654 claims |
| AstraZenecaFarxiga | $355 | $29,59240 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $234 | $19,34133 claims |
| MerckJanuvia, Belsomra | $125 | $16,09231 claims |
| Johnson & JohnsonXarelto | $30 | $11,81111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Alexander Dela LlanaEvansville$1.6M
- David BrougherEvansville$556K
- Anthony InzerelloEvansville$338K
- James GutmannEvansville$311K
- Randall StoltzEvansville$248K
- William SmithEvansville$150K
- Carol GoodmanEvansville$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.